Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 7/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | QRFPR | Q96P65 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | TPO | P07202 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347208 | 0.76 | MAPT (0.45) | CCR2KCNH2MPOTPOMAPT | |
| SCHEMBL22873258 | 0.67 | AKR1B1 (0.45) | TDP1MPOTPOMAPT | |
| SCHEMBL2006946 | 0.67 | HTR2A (0.55) | LMNA | |
| SCHEMBL14615582 | 0.67 | LMNA (0.53) | MPOTPOTHRBPOLBLMNA | |
| SCHEMBL1467597 | 0.66 | CCR2 (0.54) | TDP1CCR2 | |
| SCHEMBL1467717 | 0.66 | TDP1 (0.51) | TDP1CCR2THRBMAPTLMNA | |
| SCHEMBL22003789 | 0.66 | ACLY (0.51) | TDP1CCR2 | |
| SCHEMBL12491153 | 0.65 | MAPT (0.41) | TDP1CCR2THRBMAPTLMNA | |
| SCHEMBL20037044 | 0.65 | TDP1 (0.65) | TDP1CCR2MAPTLMNA | |
| Hydrochloric Acid SCHEMBL8687669 | 0.65 | ALDH1A1 (0.52) | AHRCCR2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820672-B2 | 3-[5-chloro-6-methyl-2-(4-methyl-piperazin-1-yl)-pyrimidin-4-yl]-4-( 1H-indol-3-yl)-pyrrole-2,5-dione; T lymphocytes, Protein Kinase C (PKC) and glycogen synthase kinase 3 beta (GSK3B) mediated diseases; | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| US-20060058356-A1 | Indolylmaleimide derivatives | NOVARTIS AG | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058356-A1 | Indolylmaleimide derivatives | GSK3B, GSK3A, GSKIP | TDP1 1134/4885AHR 3622/4885CCR2 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.